Hasil Pencarian - Barbara Eichhorst

Perbaiki Hasil
  1. 1
    Sequential and combination treatments with novel agents in chronic lymphocytic leukemia

    Sequential and combination treatments with novel agents in chronic lymphocytic leukemia oleh Moritz Fürstenau, Michael Hallek, Barbara Eichhorst

    Diterbitkan 2019-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia

    EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia oleh Barbara Eichhorst, Paolo Ghia, on behalf of the EHA Guidelines Committee

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?

    Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine? oleh Moritz Fürstenau, Nisha De Silva, Barbara Eichhorst, Michael Hallek

    Diterbitkan 2019-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Invasive Aspergillosis in Patients Treated With Ibrutinib

    Invasive Aspergillosis in Patients Treated With Ibrutinib oleh Moritz Fürstenau, Florian Simon, Oliver A. Cornely, Tillman Hicketier, Barbara Eichhorst, Michael Hallek, Sibylle C. Mellinghoff

    Diterbitkan 2020-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)

    P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) oleh Barbara Eichhorst, Nicole Lamanna, Susan O’brien, Constantine Tam, Lugui Qiu, Keri Yang, Ken Wu, Tommi Salmi, Gisoo Barnes, Jennifer R. Brown

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials

    Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials oleh Valentin Goede, Paula Cramer, Raymonde Busch, Manuela Bergmann, Martina Stauch, Georg Hopfinger, Stephan Stilgenbauer, Hartmut Döhner, Anne Westermann, Clemens M. Wendtner, Barbara Eichhorst, Michael Hallek

    Diterbitkan 2014-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia

    Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia oleh Othman Al-Sawaf, Carmen Diana Herling, Udo Holtick, Christoph Scheid, Paula Cramer, Stephanie Sasse, Bastian von Tresckow, Armin Tuchscherer, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Lukas P. Frenzel

    Diterbitkan 2019-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)

    Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG) oleh Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, Jasmin Bahlo, Sandra Robrecht, Eugen Tausch, Johannes Bloehdorn, Manuela Hoechstetter, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Michael Hallek, Hartmut Döhner, Richard Rosenquist, Paolo Ghia, Kostas Stamatopoulos, Stephan Stilgenbauer

    Diterbitkan 2019-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)

    Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440) oleh Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, Guillaume Cartron, Michael Hallek, Barbara Eichhorst, Mark F. Kozloff, Thomas Giever, Gerard Lozanski, Yanwen Jiang, Huang Huang, Daniela Soriano Pignataro, William Schary, Kathryn Humphrey, Mehrdad Mobasher, Gilles Salles

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    P631: CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL TRIAL SAFETY DATABASE

    P631: CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL... oleh Jennifer R. Brown, Barbara Eichhorst, Paolo Ghia, Wojciech Jurczak, Brad Kahl, Nicole Lamanna, Tadeusz Robak, Mazyar Shadman, Constantine Tam, Lugui Qiu, Aileen Cohen, Meng Zhang, Tommi Salmi, Jason Paik, Liping Wang, Jun Zhang, Han MA, Alessandra Tedeschi

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia

    SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia oleh Sibylle C. Mellinghoff, Leonie Mayer, Sandra Robrecht, Leonie M. Weskamm, Christine Dahlke, Henning Gruell, Maike Schlotz, Kanika Vanshylla, Hans A. Schloser, Martin Thelen, Anna-Maria Fink, Kirsten Fischer, Florian Klein, Marylyn M. Addo, Barbara Eichhorst, Michael Hallek, Petra Langerbeins

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies

    Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies oleh Natali Pflug, Geothy Chakupurakal, Anna-Maria Fink, Sandra Robrecht, Marco Herling, Paula Cramer, Udo Holtick, Sebastian Theurich, Johannes Schetelig, Kirsten Fischer, Matthias Ritgen, Christof Scheid, Barbara Eichhorst, Peter Dreger, Michael Hallek, Michael von Bergwelt-Baildon, on behalf of the German CLL Study Group

    Diterbitkan 2021-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)

    Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCL... oleh Paula Cramer, Susanne Isfort, Jasmin Bahlo, Stephan Stilgenbauer, Hartmut Döhner, Manuela Bergmann, Martina Stauch, Michael Kneba, Elisabeth Lange, Petra Langerbeins, Natali Pflug, Gabor Kovacs, Valentin Goede, Anna-Maria Fink, Thomas Elter, Kirsten Fischer, Clemens-Martin Wendtner, Michael Hallek, Barbara Eichhorst

    Diterbitkan 2015-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS

    P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BI... oleh Deyan Yosifov, Julia von Tresckow, Adam Giza, Sandra Robrecht, Christof Schneider, Billy Jebaraj, Daniel Mertens, Matthias Ritgen, Anke Schilhabel, Karl-Anton Kreuzer, Anna Maria Fink, Othman Al-Sawaf, Petra Langerbeins, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer, Paula Cramer, Eugen Tausch

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)

    S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CL... oleh Arnon Kater, Rosemary Harrup, Thomas J Kipps, Barbara Eichhorst, Carolyn J Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Maria Thadani-Mulero, Marcus Lefebure, Yanwen Jiang, Rosemary Millen, Michelle Boyer, John F Seymour

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

    Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia oleh Nadine Kutsch, Christian Pallasch, Thomas Decker, Holger Hebart, Kai Uwe Chow, Ullrich Graeven, Jens Kisro, Alexander Kroeber, Eugen Tausch, Kirsten Fischer, Anna-Maria Fink, Clemens-Martin Wendtner, Matthias Ritgen, Stephan Stilgenbauer, Danjie Zhang, Biao Li, Juliane M. Jürgensmeier, Nishanthan Rajakumaraswamy, Pankaj Bhargava, Michael Hallek, Barbara Eichhorst

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

    S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY oleh Othman Al-Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna-Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Liliya Sivcheva, Carsten Niemann, Anthony Schwarer, Javier Loscertales Pueyo, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Eva Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL

    P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PH... oleh Florian Simon, Rudy Ligtvoet, Thomas Noesslinger, Jan-Paul Bohn, Julia Von Tresckow, Rüdiger Liersch, Tobias Gaska, Kathleen Jentsch-Ullrich, Michael Koenigsmann, Thomas Wolff, Ingo Schwaner, Dominik Wolf, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Karl-Anton Kreuzer, Sandra Robrecht, Anna-Maria Fink, Moritz Fürstenau, Kirsten Fischer, Valentin Goede, Michael Hallek, Barbara Eichhorst

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL

    S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CO... oleh Petra Langerbeins, Sandra Robrecht, Pascal Nieper, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf, Anna-Maria Fink, Karl-Anton Kreuzer, Ursula Vehling-Kaiser, Eugen Tausch, Christof Schneider, Lothar Müller, Michael Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial

    Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial oleh Paula Cramer, Julia v. Tresckow, Sandra Robrecht, Jasmin Bahlo, Moritz Fürstenau, Petra Langerbeins, Natali Pflug, Othman Al-Sawaf, Werner J. Heinz, Ursula Vehling-Kaiser, Jan Dürig, Eugen Tausch, Manfred Hensel, Stephanie Sasse, Anna-Maria Fink, Kirsten Fischer, Karl-Anton Kreuzer, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek

    Diterbitkan 2020-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: